SILVER SPRING, Md. (October 24, 2013)--An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from a panel of government experts.
The experts say the medication should be approved to treat patients infected with the liver-destroying virus.
All 19 members of a panel of Food and Drug Administration advisers voted in favor of approving J&J's simeprevir, a daily pill designed to eliminate the most common form of hepatitis C.
The FDA is not required to follow the group's recommendation, although it often does.
A decision on the drug is expected next month.
More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year.
J&J is one of a half-dozen companies working to develop more effective treatments for the virus.